Pfizer: unveils positive data for potential Covid-19 vaccine
(CercleFinance.com) - Following a positive US study, Pfizer and partner BioNTech on Monday unveiled encouraging results from an ongoing German phase 1/2 trial on their vaccine project against Covid-19.
Overall, the data suggested that the vaccine could potentially be administered safely, with a manageable tolerability profile, the companies said.
"The preliminary data indicate that our mRNA-based vaccine was able to stimulate antibody as well as T-cell responses at remarkably low dose levels," said Ozlem Tureci, the co-founder of BioNTech.
The German trial enrolled a total of 60 healthy adults aged 18 to 55.
Pfizer and partner BioNTech said they expect a global phase 2b/3 safety and efficacy trial that may involve up to 30,000 healthy participants to begin in late July, if regulatory approval is received.
Pfizer shares were up over 2% on the New York Stock Exchange on Monday morning, while the BioNTech stock jumped 9%.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Overall, the data suggested that the vaccine could potentially be administered safely, with a manageable tolerability profile, the companies said.
"The preliminary data indicate that our mRNA-based vaccine was able to stimulate antibody as well as T-cell responses at remarkably low dose levels," said Ozlem Tureci, the co-founder of BioNTech.
The German trial enrolled a total of 60 healthy adults aged 18 to 55.
Pfizer and partner BioNTech said they expect a global phase 2b/3 safety and efficacy trial that may involve up to 30,000 healthy participants to begin in late July, if regulatory approval is received.
Pfizer shares were up over 2% on the New York Stock Exchange on Monday morning, while the BioNTech stock jumped 9%.
Copyright (c) 2020 CercleFinance.com. All rights reserved.